Prolactin: a diabetogenic hormone.
During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in second OGTT. Human PRL or CB 154 had no significant influence on  insulin release due to glucose in the perfused rat pancreas. These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours.
D000236:Adenoma / Q000097:blood; D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001971:Bromocriptine / Q000494:pharmacology; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood; D011388:Prolactin / Q000097:blood / Q000494:pharmacology; D051381:Rats
D001786:Blood Glucose; D007328:Insulin; D001971:Bromocriptine; D011388:Prolactin